High dose chemotherapy effective in patients with recurrent testicular cancer

September 28, 2000

High-dose chemotherapy followed by stem-cell transplantation offers new hope to testicular cancer patients who experience cancer recurrence. For these patients, such intensive therapy can achieve a durable remission in approximately 50% of patients, according to a study conducted at Indiana University Medical Center.

In the largest study to date, after an average of more than three years of follow-up, 37 (or 57%) of 65 patients with recurrent testicular cancer were disease-free after receiving two rounds of high-dose chemotherapy followed by stem-cell transplantation. These results are significant says the study's lead author, Lawrence H. Einhorn, M.D., because if testicular cancer recurs, it often develops within a year after treatment. All patients in this study had a minimal follow-up of 16 months.

Researchers say the advance is remarkable because it demonstrates how the battle against testicular cancer is being won. Already, 70% of patients are cured with initial chemotherapy. This study shows that for the remaining 30% of patients who did not respond to the treatment or who later relapsed, more than half can be cured with a second round of intensive chemotherapy - bringing the overall cure rate to approximately 85 percent.

"This is a message of hope," says Dr. Einhorn. "For patients who are not cured with the initial chemotherapy, we can now tell them with confidence that there is more than a 50% chance they can still be cured with second-line therapy."

Historically, high-dose chemotherapy was viewed as a treatment of last resort for testicular cancer because of its toxicity, especially when combined with bone marrow transplants. But with the more recent ability to extract stem cells from the blood, not the marrow, effectiveness has increased, the severity of side effects has decreased, and the financial cost has lessened. The majority of this therapy is currently conducted in the outpatient unit.
-end-
"High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular Cancer;" Lawrence H. Einhorn, MD, et al.; Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center, Indianapolis, IN. Vol. 18, No. 19 (October), 2000: pp 3346-3351.

American Society of Clinical Oncology

Related Testicular Cancer Articles from Brightsurf:

Diagnostic imaging may increase risk of testicular cancer
Early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer.

UT southwestern levels the playing field for testicular cancer patients
DALLAS - Aug. 10, 2020 - By offering the same level of care and expertise to two very different populations, UT Southwestern physicians were able to eliminate the sociodemographic disparities in survival and cancer recurrence rates typically seen nationally in testicular cancer patients.

Standardized care may help equalize health outcomes among patients with testicular cancer
New research suggests that although sociodemographic factors have been associated with poor outcomes for patients treated for testicular cancer, guideline-directed, expert care can help to address this issue.

Healthy offspring from testicular tissue plantation in mice: Retinoic acid key
Germ cell depletion in recipient testis has adverse effects on spermatogenesis in orthotopically transplanted testis pieces via retinoic acid insufficiency.

Side effects of testicular cancer predicted by machine learning
In collaboration with Rigshospitalet, researchers from DTU Health Technology have developed a machine learning model that can predict chemotherapy-associated nephrotoxicity, a particularly significant side effect in patients treated with cisplatin.

Preservation of testicular cells to save endangered feline species
A research team at the German Leibniz Institute for Zoo and Wildlife Research (Leibniz-IZW) developed a method to isolate and cryopreserve testicular cells.

Observational study explores fish oil supplements, testicular function in healthy young men
An observational study of nearly 1,700 young healthy Danish men looked at how fish oil supplements were associated with testicular function as measured by semen quality and reproductive hormone levels.

Half the amount of chemo prevents testicular cancer from coming back, new trial shows
Testicular cancer can be prevented from coming back using half the amount of chemotherapy that is currently used, a new clinical trial has shown.

Chlamydia in testicular tissue linked to male infertility
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study led by scientists at Queensland University of Technology (QUT), which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause.

Scientists discover autoimmune disease associated with testicular cancer
Using advanced technology, scientists at Chan Zuckerberg (CZ) Biohub, Mayo Clinic and University of California, San Francisco (UCSF), have discovered an autoimmune disease that appears to affect men with testicular cancer.

Read More: Testicular Cancer News and Testicular Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.